about
Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genesThe associations between Parkinson's disease and cancer: the plot thickensPathologic and therapeutic implications for the cell biology of parkinIncreasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene.Parkin regulates translesion DNA synthesis in response to UV radiationA recurrent mutation in PARK2 is associated with familial lung cancer.Genomic and Functional Analysis of the E3 Ligase PARK2 in Glioma.Structural and Functional Impact of Parkinson Disease-Associated Mutations in the E3 Ubiquitin Ligase ParkinSplicing: is there an alternative contribution to Parkinson's disease?Altered Mitochondrial Respiration and Other Features of Mitochondrial Function in Parkin-Mutant Fibroblasts from Parkinson's Disease Patients.Association of a PARK2 Germline Variant and Epithelial Ovarian Cancer in a Southern Brazilian Population.Copy number variation in archival melanoma biopsies versus benign melanocytic lesions.Inactivation of parkin by promoter methylation correlated with lymph node metastasis and genomic instability in nasopharyngeal carcinoma.Specificity and disease in the ubiquitin systemParkin modulates expression of HIF-1α and HIF-3α during hypoxia in gliobastoma-derived cell lines in vitro.Parkin and mitophagy in cancer.A Review on Ubiquitination of Neurotrophin Receptors: Facts and Perspectives.PARK2 negatively regulates the metastasis and epithelial-mesenchymal transition of glioblastoma cells via ZEB1.Parkin in cancer: Mitophagy-related/unrelated tasks.Do mitochondria donate membrane to form autophagosomes or undergo remodeling to form mitochondrial spheroids?Beyond Mitophagy: The Diversity and Complexity of Parkin Function.Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression.Differential expression of PARK2 splice isoforms in an in vitro model of dopaminergic-like neurons exposed to toxic insults mimicking Parkinson's disease.Mechanisms, pathophysiological roles and methods for analyzing mitophagy - recent insights.PARK2 inhibits osteosarcoma cell growth through the JAK2/STAT3/VEGF signaling pathway.
P2860
Q26772317-ECD729DE-5674-4F82-A69D-AF8401DC10BCQ26778641-E59C7568-1332-4044-9C94-DFD0A32FD124Q27010567-352E5B9F-5625-4AAD-983A-E325A75694C1Q33782133-49B85865-AFA4-4A26-965F-172220743D56Q33829515-21384ECA-3C5E-4B3B-8450-2C8375737E27Q35059365-4FD1BE7E-295D-4E14-B843-F08CA46BD466Q35562809-5062CE89-90AA-4CD1-8F02-D931761AA3B1Q35888058-4FA41432-9D4B-4196-A8CF-54CB482EBF3CQ36069844-70DAF863-E4A5-4327-9D64-DD84945C3D1AQ36726882-16E6A8EC-F854-499F-8D4E-2B24FD4AD2A3Q37171049-43E8BEBE-BF36-4326-9320-EACACD68AAADQ38381518-240908EF-4EFB-4924-9966-0F715BB2CB35Q38709886-5CE4124D-58A9-4395-B6D9-43488FADB4E0Q38728113-934FA57B-537C-44CB-8AFB-5C1570F7FE9FQ38805814-73DEBAF0-46E0-4397-A0A4-9829E8D69956Q38946190-88BC260B-14E6-467E-989E-823630852F81Q39196632-EEFCBF3E-D825-49F9-9964-4F8D41FCF251Q41611419-773DC353-8125-4A42-B0AC-F556B84F8031Q42317723-5F31F794-84D3-415C-B3B3-94BEFC663749Q43043864-CE9EB79C-4DCC-4935-A4A6-951BF8A0BFDAQ44935739-C81D7C8F-DE48-4947-8032-C3B642DDF065Q47132104-13692F42-2D43-459A-BE9A-00678747676BQ48157376-1C33DCD1-305D-4AA4-9628-C19F6F0C4F49Q49612593-37F4D038-8292-49D8-90F5-AA9134AFB972Q52728102-3B97FB2A-5E9F-4173-9B63-AE9D55FFC2F5
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
An emerging role of PARK2 in cancer.
@en
type
label
An emerging role of PARK2 in cancer.
@en
prefLabel
An emerging role of PARK2 in cancer.
@en
P2860
P1476
An emerging role of PARK2 in cancer.
@en
P2093
H Phillip Koeffler
P2860
P2888
P356
10.1007/S00109-013-1107-0
P577
2013-12-03T00:00:00Z
P5875
P6179
1050056015